Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ImmunityBioSTU:26CA +2.55%64 Days Payable is 3,553.80 as of Jun. 2026, which is 7% above its 10-year median of 3,321.11. GuruFocus rates STU:26CA with a GF Score™ of 64/100 and a GF Value™ of €19.21 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 708 Biotechnology companies, ImmunityBio ranks better than 92.23% on this metric.
ImmunityBio's average Accounts Payable for the
three
months ended in Jun. 2026 was €10.0 Mil. ImmunityBio's Cost of Goods Sold for the
three
months ended in Jun. 2026 was €0.3 Mil.
Hence, ImmunityBio's Days Payable for the
three
months ended in Jun. 2026 was 3,553.80.
The historical rank and industry rank for ImmunityBio's Days Payable or its related term are showing as below:
STU:26CA'
s Days Payable Range Over the Past 10 Years
Min: 2890.73 Med: 3321.11 Max: 3321.11
Current: 2890.73
During the past 7 years, ImmunityBio's highest Days Payable was 3321.11. The lowest was 2890.73. And the median was 3321.11.
STU:26CA's Days Payable is ranked better than 92.23% of 708
companies
in the Biotechnology industry
Industry Median: 111.165
vs STU:26CA: 2890.73
ImmunityBio's Days Payable
declined
from Jun. 2025 (7,377.99) to Jun. 2026 (3,553.80).
It may suggest that ImmunityBioaccelerated paying its suppliers.
The historical data trend for ImmunityBio's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:26CA vs RYTM, PCVX, MIRM: Days Payable Comparison
For the Biotechnology subindustry, ImmunityBio's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ImmunityBio Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ImmunityBio's Days Payable distribution charts can be found below:
* The bar in red indicates where ImmunityBio's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
ImmunityBio's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ImmunityBio (STU:26CA) has a Days Payable of 3,553.80 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on ImmunityBio and its competitors. This is near median its historical median of 3,321.11. Over the past decade, ImmunityBio's Days Payable has ranged from 2,890.73 to 3,321.11. According to the industry distribution chart, ImmunityBio ranks #55 out of 708 companies in the Biotechnology industry, placing it in the top 7.8%.
Is ImmunityBio's Days Payable too high?
ImmunityBio's current Days Payable of 3,553.80 is near median its 10-year median of 3,321.11. Over the past 10 years, this metric has ranged from a low of 2,890.73 to a high of 3,321.11. The Biotechnology industry median Days Payable is 111.17. ImmunityBio's value of 3,553.80 is 3096.9% above this industry median. Based on the distribution chart, ImmunityBio ranks #55 out of 708 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, ImmunityBio has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ImmunityBio's Days Payable compare to RYTM and PCVX?
According to the Biotechnology industry distribution chart, ImmunityBio ranks #55 out of 708 companies for Days Payable. This places ImmunityBio in the top 8% of its industry — outperforming the majority of peers. The industry median Days Payable is 111.17. ImmunityBio's value of 3,553.80 is 3096.9% above this benchmark. Historically, ImmunityBio's own Days Payable has ranged from 2,890.73 to 3,321.11 over the past decade. While the company's 10-year median is 3,321.11 vs. the industry median of 111.17, ImmunityBio has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 111.17, based on 708 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ImmunityBio's current Days Payable of 3,553.80 is 3096.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on ImmunityBio and its competitors. For the Biotechnology industry, the median Days Payable is 111.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ImmunityBio's current Days Payable is 3,553.80, which is near median its own 10-year median of 3,321.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ImmunityBio stock overvalued right now?
Based on GuruFocus' analysis, ImmunityBio (STU:26CA) is currently considered Possible Value Trap. The stock's GF Value™ is €19.21, compared to a current price of €7.25 — trading 62.3% below its estimated fair value. The current Days Payable is 3,553.80, which is near median its 10-year median of 3,321.11 and 3096.9% above the Biotechnology industry median of 111.17. ImmunityBio's overall GF Score™ is 64/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For ImmunityBio (STU:26CA), the current Days Payable is 3,553.80 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ImmunityBio (STU:26CA) Overvalued in 2026?
Based on GuruFocus' analysis, ImmunityBio stock appears to be undervalued.
The current stock price of €7.25 is trading 62.3% below its estimated GF Value™ of €19.21.
GuruFocus considers ImmunityBio to be Possible Value Trap.
Key valuation signals for STU:26CA:
Days Payable: 3,553.80 (near median its 10-year median of 3,321.11)
GF Value™: €19.21 vs. price of €7.25 (62.3% below fair value)
Industry Position: 3096.9% above the Biotechnology median (#55 of 708)
No single metric tells the full story. See the STU:26CA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
64GF Score
Get the complete analysis for STU:26CA
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:26CA has been successfully added to your 
